Controversies in Neuro-Oncology

Avastin and Malignant Gliomas

Indexed in: Chemical Abstracts, EBSCO, Ulrich's Periodicals Directory.

Neuro-oncology is an embryonic field of cancer research with a number of clinical trials in progress. However, the prognosis on neuro-oncologic patients has remained poor. Moreover, several small ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



The Radiographic Interpretation of Response to Avastin in Glioblastoma Multiforme

Pp. 74-80 (7)

Nicholas Butowski and Susan Chang

Abstract

Avastin generates a decrease in vascular permeability in GBM which is marked by a decrease in cerebral edema and a decrease in contrast enhancement as seen on magnetic resonance imaging. These effects on the tumor vasculature may be mistakenly referred to as tumor responses because the historical method of measuring tumor response is based on tumor size assessed by contrast enhancement. This may explain why the few prospective phase II trials and several retrospective studies of Avastin in GBM report high radiographic response rates (30-60%) but modest improvements in progression-free survival and overall survival. Improved radiographic criteria for detecting disease progression in this context are needed and should be used in larger, randomized clinical trials which determine the magnitude of the survival benefit from Avastin.

Affiliation:

Department of Neuro-Oncology, Brain Tumor Research Center, University of California, San Francisco, San Francisco, California, 400 Parnassus Avenue, A808, San Francisco, California 94143-0350.